Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pandemic Will Continue Limiting US FDA Inspections In Driving FY 2021 Drug GMP Warnings

Jan 04 2021

• By Bowman Cox

Related Content

The Quality Lowdown: COVID-19's Pressures On Drug Quality

Aug 13 2020

US FDA Invites Warning Letter Follow-Up Inspection Alternative Proposals As Pandemic Persists

Jul 01 2020

Deadly COVID-19 Hand Sanitizer Production Surge Prompted US FDA's New Import Alert Category

Sep 18 2020

US FDA Assesses Over 500 Biopharma Plants Remotely Via Records Review; Refines Process

Sep 17 2020

US FDA Gets Lesson In 'Unintended Consequences' From Relaxing Sanitizer Production Standards

Dec 08 2020

OTC Sanitizers Lather Up US Drug Recalls In 2020

Dec 31 2020

US FDA Adds Hand Sanitizer Import Alert Category After COVID-19 Production Surge Turned Deadly

Sep 18 2020

What The FDA’s Inspections Q&A Guidance Really Means: It’s Time To Offer Virtual Inspections

Sep 11 2020

Additional Topics

International United States FDA OTC Drugs Regulation Commercial Compliance Coronavirus COVID-19 Drug Approval Standards Enforcement Ingredients Manufacturing Policy Safety Consumer

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window